Dias David M, Ciulli Alessio
Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK.
College of Life Sciences, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dow Street, DD1 5EH, Dundee, UK.
Prog Biophys Mol Biol. 2014 Nov-Dec;116(2-3):101-12. doi: 10.1016/j.pbiomolbio.2014.08.012. Epub 2014 Aug 28.
Nuclear magnetic resonance (NMR) spectroscopy is a pivotal method for structure-based and fragment-based lead discovery because it is one of the most robust techniques to provide information on protein structure, dynamics and interaction at an atomic level in solution. Nowadays, in most ligand screening cascades, NMR-based methods are applied to identify and structurally validate small molecule binding. These can be high-throughput and are often used synergistically with other biophysical assays. Here, we describe current state-of-the-art in the portfolio of available NMR-based experiments that are used to aid early-stage lead discovery. We then focus on multi-protein complexes as targets and how NMR spectroscopy allows studying of interactions within the high molecular weight assemblies that make up a vast fraction of the yet untargeted proteome. Finally, we give our perspective on how currently available methods could build an improved strategy for drug discovery against such challenging targets.
核磁共振(NMR)光谱法是基于结构和基于片段的先导化合物发现的关键方法,因为它是在溶液中原子水平上提供有关蛋白质结构、动力学和相互作用信息的最可靠技术之一。如今,在大多数配体筛选流程中,基于NMR的方法被用于识别小分子结合并进行结构验证。这些方法可以是高通量的,并且经常与其他生物物理分析协同使用。在这里,我们描述了用于辅助早期先导化合物发现的现有基于NMR实验组合的当前技术水平。然后,我们将重点关注多蛋白复合物作为靶点,以及NMR光谱法如何用于研究构成绝大部分尚未靶向的蛋白质组的高分子量组装体中的相互作用。最后,我们就目前可用的方法如何构建针对此类具有挑战性靶点的改进药物发现策略发表我们的观点。